Decreased bone mineralization in children with Noonan syndrome: Another consequence of dysregulated RAS MAPKinase pathway?

Molecular Genetics and Metabolism

Volumn 106, Issue 2, 2012, Pages 237-240

  Choudhry, Kiran S ^a   Grover, Monica ^a   Tran, Alyssa A ^a   O'Brian Smith, E ^a   Ellis, Kenneth J ^a   Lee, Brendan H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bone mineral density; DXA; Noonan syndrome; RAS MAPK pathway

Indexed keywords

CALCIUM PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SOMATOMEDIN C; SOS PROTEIN;

ADOLESCENT; AGE; ARTICLE; BODY HEIGHT; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; GAIN OF FUNCTION MUTATION; GENDER; GENE MUTATION; GENETIC SCREENING; HUMAN; MALE; MOLECULAR DIAGNOSIS; NOONAN SYNDROME; OSSIFICATION; OSTEOLYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; BONE AND BONES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NOONAN SYNDROME; ONCOGENE PROTEIN P21(RAS);

EID: 84860914935     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.04.003     Document Type: Article

References (32)

1. Gelb B.D., Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 2006, 15(Spec No 2):R220-R226.
2. Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., Dallapiccola B., Gelb B.D., Tartaglia M. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am. J. Hum. Genet. 2006, 79:129-135.
3. Schubbert S., Zenker M., Rowe S.L., Boll S., Klein C., Bollag G., van der Burgt I., Musante L., Kalscheuer V., Wehner L.E., Nguyen H., West B., Zhang K.Y., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., Kratz C.P. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 2006, 38:331-336.
4. Zenker M., Horn D., Wieczorek D., Allanson J., Pauli S., van der Burgt I., Doerr H.G., Gaspar H., Hofbeck M., Gillessen-Kaesbach G., Koch A., Meinecke P., Mundlos S., Nowka A., Rauch A., Reif S., von Schnakenburg C., Seidel H., Wehner L.E., Zweier C., Bauhuber S., Matejas V., Kratz C.P., Thomas C., Kutsche K. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J. Med. Genet. 2007, 44:651-656.
5. Tartaglia M., Martinelli S., Cazzaniga G., Cordeddu V., Iavarone I., Spinelli M., Palmi C., Carta C., Pession A., Arico M., Masera G., Basso G., Sorcini M., Gelb B.D., Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004, 104:307-313.
6. Dulai S., Briody J., Schindeler A., North K.N., Cowell C.T., Little D.G. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J. Pediatr. Orthop. 2007, 27:472-475.
7. Lammert M., Kappler M., Mautner V.F., Lammert K., Storkel S., Friedman J.M., Atkins D. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos. Int. 2005, 16:1161-1166.
8. Stevenson D.A., Moyer-Mileur L.J., Murray M., Slater H., Sheng X., Carey J.C., Dube B., Viskochil D.H. Bone mineral density in children and adolescents with neurofibromatosis type 1. J. Pediatr. 2007, 150:83-88.
9. Brunetti-Pierri N., Doty S.B., Hicks J., Phan K., Mendoza-Londono R., Blazo M., Tran A., Carter S., Lewis R.A., Plon S.E., Phillips W.A., O'Brian Smith E., Ellis K.J., Lee B. Generalized metabolic bone disease in neurofibromatosis type I. Mol. Genet. Metab. 2008, 94:105-111.
10. Duman O., Ozdem S., Turkkahraman D., Olgac N.D., Gungor F., Haspolat S. Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1. Brain Dev. 2008, 30:584-588.
11. Illes T., Halmai V., de Jonge T., Dubousset J. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos. Int. 2001, 12:823-827.
12. Kuorilehto T., Poyhonen M., Bloigu R., Heikkinen J., Vaananen K., Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos. Int. 2005, 16:928-936.
13. Tucker T., Schnabel C., Hartmann M., Friedrich R.E., Frieling I., Kruse H.P., Mautner V.F., Friedman J.M. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J. Med. Genet. 2009, 46:259-265.
14. Yilmaz K., Ozmen M., Bora Goksan S., Eskiyurt N. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr. 2007, 96:1220-1222.
15. Kolanczyk M., Kossler N., Kuhnisch J., Lavitas L., Stricker S., Wilkening U., Manjubala I., Fratzl P., Sporle R., Herrmann B.G., Parada L.F., Kornak U., Mundlos S. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 2007, 16:874-886.
16. Yang F.C., Chen S., Robling A.G., Yu X., Nebesio T.D., Yan J., Morgan T., Li X., Yuan J., Hock J., Ingram D.A., Clapp D.W. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J. Clin. Invest. 2006, 116:2880-2891.
17. Heerva E., Peltonen S., Svedstrom E., Aro H.T., Vaananen K., Peltonen J. Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone Mar 2012, 50(3):798-803.
18. Stevenson D.A., Schwarz E.L., Carey J.C., Viskochil D.H., Hanson H., Bauer S., Weng H.Y., Greene T., Reinker K., Swensen J., Chan R.J., Yang F.C., Senbanjo L., Yang Z., Mao R., Pasquali M. Bone resorption in syndromes of the Ras/MAPK pathway. Clin. Genet. 2011, 80:566-573.
19. Takagi M., Miyashita Y., Koga M., Ebara S., Arita N., Kasayama S. Estrogen deficiency is a potential cause for osteopenia in adult male patients with Noonan's syndrome. Calcif. Tissue Int. 2000, 66:200-203.
20. Noordam C., Span J., van Rijn R.R., Gomes-Jardin E., van Kuijk C., Otten B.J. Bone mineral density and body composition in Noonan's syndrome: effects of growth hormone treatment. J. Pediatr. Endocrinol. Metab. 2002, 15:81-87.
21. Reinker K.A., Stevenson D.A., Tsung A. Orthopaedic conditions in Ras/MAPK related disorders. J. Pediatr. Orthop. 2011, 31:599-605.
22. Angus R.M., Sambrook P.N., Pocock N.A., Eisman J.A. A simple method for assessing calcium intake in Caucasian women. J. Am. Diet. Assoc. 1989, 89:209-214.
23. Ellis K.J., Shypailo R.J., Hardin D.S., Perez M.D., Motil K.J., Wong W.W., Abrams S.A. Z score prediction model for assessment of bone mineral content in pediatric diseases. J. Bone Miner. Res. 2001, 16:1658-1664.
24. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., Lange B.J., Freedman M.H., McCormick F., Jacks T., Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 1996, 12:144-148.
25. McCormick F. Ras signaling and NF1. Curr. Opin. Genet. Dev. 1995, 5:51-55.
26. Klein B.Y., Rojansky N., Gal I., Shlomai Z., Liebergall M., Ben-Bassat H. Analysis of cell-mediated mineralization in culture of bone-derived embryonic cells with neurofibromatosis. J. Cell. Biochem. 1995, 57:530-542.
27. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., Tanaka S. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 2000, 148:333-342.
28. Wu X., Estwick S.A., Chen S., Yu M., Ming W., Nebesio T.D., Li Y., Yuan J., Kapur R., Ingram D., Yoder M.C., Yang F.C. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum. Mol. Genet. 2006, 15:2837-2845.
29. Yu X., Chen S., Potter O.L., Murthy S.M., Li J., Pulcini J.M., Ohashi N., Winata T., Everett E.T., Ingram D., Clapp W.D., Hock J.M. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005, 36:793-802.
30. Nakamura H., Hirata A., Tsuji T., Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J. Bone Miner. Res. 2003, 18:1198-1205.
31. Seitz S., Schnabel C., Busse B., Schmidt H.U., Beil F.T., Friedrich R.E., Schinke T., Mautner V.F., Amling M. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos. Int. 2010, 21:119-127.
32. Digilio M.C., Sarkozy A., Capolino R., Chiarini Testa M.B., Esposito G., de Zorzi A., Cutrera R., Marino B., Dallapiccola B. Costello syndrome: clinical diagnosis in the first year of life. Eur. J. Pediatr. 2008, 167:621-628.